ArticleOpen forum infectious diseases2026
Drug-Resistant Tuberculosis Outcomes in South Kivu Province, Democratic Republic of Congo, During a Humanitarian Crisis (2018-2024).
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-resistant tuberculosis (DR-TB) management in fragile, conflict-affected settings remains challenging. South Kivu Province has faced protracted insecurity and recent outbreaks (COVID-19, mpox). We assessed treatment outcomes and predictors among DR-TB patients managed under programmatic conditions. Methods: We conducted a retrospective provincial cohort study of all patients registered in electronic Tuberculosis registry with DR-TB in South Kivu from January 2018 to June 2024. Primary outcome was treatment success; unsuccessful outcomes. We summarized characteristics, performed Kaplan-Meier functions for time to outcome, and fitted multivariable logistic regression and Cox proportional hazards models to identify predictors of unsuccessful outcomes. Results: Among 277 DR-TB patients (median age 37 years; 3-75), overall treatment success was 77.6%, mortality 13.4%, and loss to follow-up (LTFU) 8.6%. HIV status was negative in 79.1% and positive in 9.4%. Bedaquiline-containing regimens were used in 100%. In adjusted analyses, rural residence was protective against unsuccessful outcome (aOR 0.42; 95% CI 0.21-0.82; Conclusions: In a humanitarian crisis context, programmatic all-oral DR-TB care achieved success exceeding the WHO ≥ 75% target. Persistently high mortality and LTFU-concentrated among urban residents and retreatment (non-relapse) cases-highlight the need for targeted urban patient-tracing, strengthened referral/continuity mechanisms, and uninterrupted drug supply. Results support scale-up of short, all-oral regimens with context-specific adherence support in fragile settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.